Literature DB >> 31283891

Efficacy and Safety of Topical Chloroquine in Mild to Moderate Dry Eye Disease.

Jeewan S Titiyal1, Manpreet Kaur1, Ruchita Falera1, Ashima Bharghava1, Ramkishor Sah1, Seema Sen2.   

Abstract

Purpose: To evaluate the role of topical chloroquine (CHQ) as an adjunct to topical lubricants in the management of mild-moderate dry eye disease (DED)
Methods: Prospective comparative pilot study allocated 150 patients with symptoms of mild to moderate DED to receive topical CMC 0.5% three times a day (group I, n = 75) or topical CHQ 0.03% twice a day with carboxymethylcellulose (CMC) 0.5% three times a day (group II, n = 75), for three months. Primary outcome measures were ocular surface disease index (OSDI) score and conjunctival impression cytology at 3 months. Secondary outcome measures were TBUT, Schirmer's test, ocular surface staining and any adverse effects at 3 months. Follow up was performed at 1 and 3 months.
Results: At three months, the OSDI score was significantly better in the CHQ group as compared with the CMC group (CMC-18.36 ± 4.03 (SD), CHQ group- 15.9 ± 5.18 (SD); p = .002). Nelson's score was 0.92 ± 0.69 (SD) in the CHQ group as compared with 1.60 ± 0.77 (SD) in the CMC group (p < .001). Abnormal impression cytology was observed in 20% cases in the CHQ group as compared with 61.3% cases in CMC group (p < .001). A significant correlation was observed between Nelson's score and OSDI (Spearman's rho correlation coefficient 0.414, p < .001). TBUT, Schirmer test and ocular surface staining were significantly better in the CHQ group (p < .001). No adverse effects were observed in any group.
Conclusion: Topical chloroquine is a useful adjunct to topical lubricants in the management of DED as it decreases the underlying chronic inflammation and helps maintain ocular surface stability.

Entities:  

Keywords:  Dry eye disease; Topical Chloroquine; anti-inflammatory therapy; impression cytology

Mesh:

Substances:

Year:  2019        PMID: 31283891     DOI: 10.1080/02713683.2019.1641824

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  4 in total

1.  Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.

Authors:  Alok Thakar; Smriti Panda; Pirabu Sakthivel; Megha Brijwal; Shivram Dhakad; Avinash Choudekar; Anupam Kanodia; Sushma Bhatnagar; Anant Mohan; Subir K Maulik; Lalit Dar
Journal:  Indian J Med Res       Date:  2021 Jan & Feb       Impact factor: 5.274

Review 2.  The eye as the discrete but defensible portal of coronavirus infection.

Authors:  Minas Theodore Coroneo
Journal:  Ocul Surf       Date:  2020-05-21       Impact factor: 5.033

Review 3.  Potential ocular and systemic COVID-19 prophylaxis approaches for healthcare professionals.

Authors:  Rohit Shetty; Vaitheeswaran Ganesan Lalgudi; Pooja Khamar; Krati Gupta; Swaminathan Sethu; Archana Nair; Santosh G Honavar; Arkasubhra Ghosh; Sharon D'Souza
Journal:  Indian J Ophthalmol       Date:  2020-07       Impact factor: 1.848

4.  COVID-19: Ophthalmic prophylactic and therapeutic measures.

Authors:  Shrikant Waikar; Avadhesh Oli
Journal:  Indian J Ophthalmol       Date:  2020-06       Impact factor: 1.848

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.